Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 1 of 1 for:    NCT01255813
Previous Study | Return to List | Next Study

Sphenopalatine Ganglion Stimulation for the Acute Treatment of Cluster Headache

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01255813
Recruitment Status : Completed
First Posted : December 7, 2010
Last Update Posted : December 29, 2015
Information provided by (Responsible Party):
Autonomic Technologies, Inc.

Brief Summary:
The purpose of the proposed clinical study is to evaluate the use of an implanted Neurostimulator to provide Sphenopalatine Ganglion (SPG) stimulation for the management of the pain associated with cluster headaches.

Condition or disease Intervention/treatment Phase
Chronic Cluster Headache Device: Stimulation (Sub-perception) Device: Stimulation (Full) Other: Control Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 43 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Sphenopalatine Ganglion Stimulation for the Acute Treatment of Cluster Headache
Study Start Date : December 2010
Actual Primary Completion Date : March 2013
Actual Study Completion Date : March 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Headache

Arm Intervention/treatment
Placebo Comparator: Placebo Other: Control
No stimulation applied

Experimental: Sub-perception Device: Stimulation (Sub-perception)
Stimulation applied below the perception threshold

Experimental: Full Stimulation Device: Stimulation (Full)
Stimulation applied above the perception threshold

Primary Outcome Measures :
  1. Number of device related Serious Adverse Events (SAEs) [ Time Frame: Implant through the Experimental Period ]
  2. Acute Pain Relief response (as defined by patient) [ Time Frame: 15 minutes ]

Secondary Outcome Measures :
  1. Pain Freedom [ Time Frame: 15 minutes ]
  2. Rescue medication use [ Time Frame: 90 minutes ]
    Use of medications to treat headache pain within 90 minutes after initiating therapy.

  3. Pain Relief after initiating therapy [ Time Frame: 30 minutes ]
  4. Pain Relief after initiating therapy [ Time Frame: 60 minutes ]
  5. Pain Relief after initiating therapy [ Time Frame: 90 minutes ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age from 18 to 65 years old (inclusive).
  • Subject has been diagnosed with chronic cluster headache according to the 2004 International Headache Society (IHS) criteria 3.1.2.
  • Subject reports a minimum of 4 cluster headaches per week.
  • Subject reports dissatisfaction with current cluster headache treatment (Criterion includes both preventive or abortive therapy per the Investigator's standard of care. Reasons for dissatisfaction with existing headache therapies may include failure of therapies, contraindication, side effects of therapies, or patient refusal of available therapies)
  • Subject is able to distinguish cluster headaches from other headaches (i.e., tension-type headaches).
  • Subject has the ability to read and comprehend, and to reliably record information as required by the Protocol.
  • Subject is able to provide written informed consent prior to participation in the study.

Exclusion Criteria:

  • Subject has had a change in type or dosage of prophylactic headache medications < one (1) month prior to study enrollment
  • Subject has undergone facial surgery in the area of the pterygopalatine fossa or zygomaticomaxillary buttress ipsilateral to the planned implant site within the last four (4) months.
  • Subject has active oral or dental abscess.
  • Subject has been treated with radiation to the facial region within the last six (6) months.
  • Subject has been diagnosed with any major infectious processes such as osteomyelitis, or primary or secondary malignancies involving the face that have been active or required treatment in the past six (6) months.
  • Subject has other significant pain problem that might confound the study assessments in the opinion of the Investigator.
  • Subject is a woman of childbearing age who is pregnant, nursing, or not using contraception.
  • Subject is currently participating or has participated in the last month in another clinical study in which the subject has, is, or will be exposed to an investigational or non-investigational drug or device.
  • Subject is felt to be at risk of non-compliance (e.g., for completing the diary or maintaining a stable headache medicine regimen) in the Investigator's opinion.
  • Subject has had previous lesional radio-frequency ablation of the ipsilateral sphenopalatine ganglion (SPG).
  • Subject has had blocks of the ipsilateral SPG in the last three (3) months.
  • Subject has undergone botulinum toxin injections of the head and/or neck in the last three (3) months.
  • Subject has or requires a pacemaker/defibrillator or other implantable device having a sense amplifier.
  • Subject has a history of bleeding disorders or coagulopathy or is unable to discontinue anticoagulation, antiplatelet, or GP IIb IIIa inhibitor medication in preparation for the implantation procedure.
  • Subject is not suitable for the study for any reason in the judgment of the Investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01255813

Layout table for location information
Citadelle Hospital
Liege, Belgium
Danish Headache Center, Dept. of Neurology, Glostrup Hospital
Glostrup, Denmark, 2600
Headache Center, Dept. of Neurology, University Duisburg-Essen
Essen, Germany, 45147
Institut fur systemische Neurowissenschaften, Universitastsklinikum Hamburg-Eppendorf (UKE)
Hamburg, Germany, 20246
Department of Neurology, University Clinic Hospital, University of Valencia
Valencia, Spain, 46010
Sponsors and Collaborators
Autonomic Technologies, Inc.
Layout table for investigator information
Principal Investigator: Jean Schoenen, M.D. Professor of Functional Neuroanatomy, Leige University
Layout table for additonal information
Responsible Party: Autonomic Technologies, Inc. Identifier: NCT01255813    
Other Study ID Numbers: Pathway CH-1 (CIP-001)
First Posted: December 7, 2010    Key Record Dates
Last Update Posted: December 29, 2015
Last Verified: December 2015
Keywords provided by Autonomic Technologies, Inc.:
Chronic Cluster Headache
Additional relevant MeSH terms:
Layout table for MeSH terms
Cluster Headache
Neurologic Manifestations
Trigeminal Autonomic Cephalalgias
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases